The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Transcatheter aortic valve replacement: a further step towards a patient-tailored therapy

EuroIntervention 2016;12:695-697. DOI: 10.4244/EIJV12I6A112

1. Department of Cardiology, Interventional Cardiology, University Hospital Antwerp, Antwerp, Belgium; 2. Department of Cardiology, Non-invasive Imaging, University Hospital Antwerp, Antwerp, Belgium

Transcatheter aortic valve replacement (TAVR) is a rapidly evolving technique providing robust treatment of severe aortic valve stenosis, at least in (very) high-risk patient cohorts. However, different important limitations, having a potential impact on patient outcome, still need to be resolved. Indeed, with several first-generation balloon-expandable or self-expanding TAVR prostheses, residual paravalvular aortic regurgitation (AR) after TAVR has been identified as a significant independent major predictor of acute and long-term mortality. Moreover, conduction disorders requiring pacemaker implantation, and also concerns about early (leaflet thrombosis/decreased leaflet motion) and late valve durability, need to be resolved before applying TAVR to ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article

Advancing with grace and effectiveness: a new constitution and renewed commitments for the EAPCI